Abstract
Tubulin protein is one of several members of a small family of globular proteins. It offers a potential target for anticancer drug design and development. Combretastatin A-4 (CA-4) is a potent anticancer and antiangiogenesis natural substance isolated from Combretum caffrum. Modifications on the CA-4 structure have led to a great number of novel CA-4 derivatives as potent tubulin inhibitors and high cytotoxic anticancer agents is becoming an interesting field, leading to a breakthrough in the treatment of cancer. In this review, the recent developments of novel CA-4 derivatives via the modifications on the A- and B-ring and the double bond as anticancer agents are discussed.
Keywords: Combretastatin A-4, Tubulin inhibitors, Anticancer, Antineoplastic Agents, Structure-Activity Relationships, antiangiogenesis, Combretum caffrum, chromo-somes, mitosis, microtu-bules, apoptosis, colchicine, vinca alka-loid domain, vinblastine, vincristine, Combretastatins, stilbenoid phenol, tubulin polymerization, chemotherapeutic, structure-activity relationship (SAR), human myelogenous leukaemia cell line, phosphate diesters, carcinoma, pinacolylboronate, boronic acid, Ethene Bridge, olefinic bridge, antineoplastic activity, hyperploid
Current Medicinal Chemistry
Title: Developments of Combretastatin A-4 Derivatives as Anticancer Agents
Volume: 18 Issue: 4
Author(s): Y. Shan Shan, J. Zhang, Z. Liu, M. Wang and Y. Dong
Affiliation:
Keywords: Combretastatin A-4, Tubulin inhibitors, Anticancer, Antineoplastic Agents, Structure-Activity Relationships, antiangiogenesis, Combretum caffrum, chromo-somes, mitosis, microtu-bules, apoptosis, colchicine, vinca alka-loid domain, vinblastine, vincristine, Combretastatins, stilbenoid phenol, tubulin polymerization, chemotherapeutic, structure-activity relationship (SAR), human myelogenous leukaemia cell line, phosphate diesters, carcinoma, pinacolylboronate, boronic acid, Ethene Bridge, olefinic bridge, antineoplastic activity, hyperploid
Abstract: Tubulin protein is one of several members of a small family of globular proteins. It offers a potential target for anticancer drug design and development. Combretastatin A-4 (CA-4) is a potent anticancer and antiangiogenesis natural substance isolated from Combretum caffrum. Modifications on the CA-4 structure have led to a great number of novel CA-4 derivatives as potent tubulin inhibitors and high cytotoxic anticancer agents is becoming an interesting field, leading to a breakthrough in the treatment of cancer. In this review, the recent developments of novel CA-4 derivatives via the modifications on the A- and B-ring and the double bond as anticancer agents are discussed.
Export Options
About this article
Cite this article as:
Shan Y. Shan, Zhang J., Liu Z., Wang M. and Dong Y., Developments of Combretastatin A-4 Derivatives as Anticancer Agents, Current Medicinal Chemistry 2011; 18 (4) . https://dx.doi.org/10.2174/092986711794480221
DOI https://dx.doi.org/10.2174/092986711794480221 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Animal Modeling of Cancer Pathology and Studying Tumor Response to Therapy
Current Drug Targets DTCM-Glutarimide Hinders Growth of Childhood Leukemia Cells but Fails to Improve the Efficacy of Commonly Used Chemotherapeutic Agents
Current Bioactive Compounds Cytotoxicity of Novel Sulfanilamides Towards Sensitive and Multidrugresistant Leukemia Cells
Current Medicinal Chemistry TNF-Related Apoptosis-Inducing Ligand (TRAIL): A Potential Candidate for Combined Treatment of Hematological Malignancies
Current Pharmaceutical Design Evolutionary Advantage and Molecular Modes of Action of Multi-Component Mixtures Used in Phytomedicine
Current Drug Metabolism Polyphenols: Biological Activities, Molecular Targets, and the Effect of Methylation
Current Molecular Pharmacology Restoration of Chemoresistance Mechanism by Novel Drug Therapies in Breast Cancer Cell Lines
Current Drug Therapy Inhibitors of HDACs - Effective Drugs Against Cancer?
Current Cancer Drug Targets Severe Hypoglycemia Due to Possible Interaction Between Glibenclamide and Sorafenib in a Patient with Hepatocellular Carcinoma
Current Drug Safety Smart Drug Release Systems Based on Stimuli-Responsive Polymers
Mini-Reviews in Medicinal Chemistry Tyrosine Kinase Inhibitors – A Review on Pharmacology, Metabolism and Side Effects
Current Drug Metabolism Spermine Metabolism and Anticancer Therapy
Current Cancer Drug Targets Immune Response Manipulation: Recombinant Immunoreceptors Endow T-Cells with Predefined Specificity
Current Pharmaceutical Design Microarrays and Colon Cancer in the Road for Translational Medicine
Current Bioinformatics Composite Lymphomas: A Challenging Entity
Current Cancer Therapy Reviews Review: Recent Clinical Trials in Epigenetic Therapy
Reviews on Recent Clinical Trials Glucocorticoid Receptors and Bone
Current Pharmaceutical Design Exploring Polypharmacology in Drug Discovery and Repurposing Using the CANDO Platform
Current Pharmaceutical Design Drug-Loaded Nanocarriers in Tumor Targeted Drug Delivery
Current Biotechnology Bhasma: Indian Perspective of Nanomedicinal Technology
Recent Patents on Nanomedicine